Dr. Darena Zlateva joins Nika Pharmaceuticals, Inc. as Chief Scientific Officer
In connection to its specialization in the pharmaceutical and biotechnological industry, Nika Pharmaceuticals, Inc. announces the appointment of Dr. Darena Zlateva as the Chief Scientific Officer (CSO) of the company. Dr. Zlateva will also serve as the Chief Scientific Officer of the subsidiary company Nika Europe, Ltd., in which Nika Pharmaceuticals now holds a 40% stake. Dr. Darena Zlateva is a highly qualified and esteemed specialist in the fields of medicine, pharmaceuticals, biotechnology, and Nika Pharmaceuticals is pleased to showcase a summary of her biography.
Dr. Darena Zlateva was born on the 15th of November, 1962 in the city of Plovdiv, Bulgaria. Dr. Zlateva became a medical doctor in 1986 when she graduated from the Plovdiv Medical University, after which she pursued a PhD degree in Immunology in the Moscow Immunology Institute, which she successfully completed in 1991. Dr. Zlateva’s hunger for knowledge is further exemplified by her post-doctoral qualification in Biochemistry (1994) from the Sofia Medical Academy, and her mastery of English, Spanish, Russian and fluency in French and Italian. Dr. Zlateva has since worked as an assistant professor in the Biochemistry Department in the Sofia Medical Academy between 1995 and 2008, after which she relocated to the heart of the European Union – Brussels, where she has been working as a Scientific and Administrative Manager for the European Medical Association and an Expert Evaluator for the Research Executive Agency (REA), which is part of the European Commission. Due to her vast academic and practical experience, Dr. Zlateva has an expertise in Project Management, an in-depth knowledge of European Union policies, and an ability to easily adapt to multicultural environments and work at an international level. Follow this link to get acquainted with the Curriculum Vitae (CV) of Dr. Zlateva.
As a CSO of Nika Pharmaceuticals, Dr. Zlateva will be responsible for the management of the operations of the company’s research projects, which includes predicting and developing research qualities (human, methodological and technological) for the development of the validity and utility of the research products. Dr. Zlateva will also serve as the connection between Nika Pharmaceuticals and the scientific and customer communities, by presenting the qualities and scientific value of the company’s products through representation of Nika Pharmaceuticals at related scientific forums and the publication of scientific publications regarding the company’s scientific developments. Dr. Zlateva will also be responsible for testing, selecting and attracting scientific personnel that is necessary for the scientific research of Nika Pharmaceuticals, as well as the selection of the scientific development projects of new products and the formulation of a long-term research strategy of the company. Dr. Zlateva will participate in the selection and evaluation of the qualities of young students who will receive scholarships connected with the scientific activity of the company in the future. In essence, Dr. Zlateva is dedicated in assisting the board of directors in all activities related to the scientific part of Nika Pharmaceuticals, Inc.
It can be summarized that the role of Dr. Zlateva encapsulates everything that is connected with science, which is good and contributes to the development and the competitive advantage of Nika Pharmaceuticals, in order to provide people with beneficial biotechnological products that are good for the human health.
—-
See the full 8K Report at sec.report.